Kisspeptin-10 vs PT-141: What the Research Shows
Kisspeptin-10 and PT-141 side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Kisspeptin-10 if…
- you want human hormone data (infusion in men; a hormone-level outcome): At 4 ug/kg/h for 22.5 h, LH rose from 5.4 to 20.8 IU/liter and testosterone from 16.6 to 24.0 nmol/liter.[13]
- you want to see the dosing limitation in women: responses fell with repeated dosing: LH and FSH responses fell sharply by day 14 of twice-daily injections (LH +2.5 IU/liter, FSH +0.5 IU/liter).[14]
Consider PT-141 if…
- you want a product with an FDA label: Vyleesi (bremelanotide) is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder[8]
- you want randomized phase 3 data (bremelanotide in premenopausal women with low desire): Desire domain score rose more than placebo: 0.30 (study 301), 0.42 (study 302), 0.35 integrated, all P<.001.[10]
- you are tested in sport and want to avoid a WADA-prohibited substance: Kisspeptin is prohibited by WADA at all times (check PT-141's own status separately)[2]
Spec comparison
Showing 10 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength are the same or both unknown.
| Field | Kisspeptin-10 | PT-141 |
|---|---|---|
| Class | GnRH stimulator | Melanocortin agonist |
| Also called | kiss | Vyleesi, PT141 |
| Category | Sexual & hormonal health | Sexual & hormonal health |
| FDA status | Not FDA approved · research chemical | FDA approved for HSDD (Vyleesi) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.1)Kisspeptin and its agonist analogues are named in S2.2.1 (testosterone-stimulating peptides in males). | Not on the WADA Prohibited ListPT-141 (bremelanotide) is not named on the list and is FDA-approved (Vyleesi), so S0 does not apply. It does not fit the named S2 subclasses. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | mean elimination half-life 1.3-2.2 hourssubcutaneous (analog MVT-602) · Fertility and sterility 2024, PMID 37925096 | approximately 2.7 hours (range 1.9-4.0 h)subcutaneous · FDA label (Vyleesi) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: European journal of endocrinology 2026, PMID 42549827 | Human RCT evidence, 4 of 4Strongest: Journal of women's health 2022, PMID 35230162 |
| Human studies we summarised | 14 human (10 randomized or controlled) of 18 summarised | 12 human (12 randomized or controlled) of 12 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 5 mg, 10 mg | 10 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Kisspeptin-10 and PT-141 together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Same complaint, completely different evidence depth
Bremelanotide's phase 3 trials had coprimary endpoints of the Female Sexual Function Index desire domain score and Female Sexual Distress Scale item 13.[10]
In the phase 3 trials, bremelanotide improved desire and related distress compared with placebo.[10]
The kisspeptin trial in women measured brain responses: kisspeptin administration modulated sexual and facial attraction brain processing.[7]
Of the 40 participants randomized in that kisspeptin trial, 32 women completed both kisspeptin and placebo visits.[7]
In the male kisspeptin data cited here, intravenous bolus kisspeptin-10 produced a rapid, dose-dependent rise in serum LH.[13]
In the phase 3 studies, patients taking bremelanotide had more nausea, flushing and headache than placebo (10% or more in both studies).[10]
Practical differences: label, schedule and limits
The Vyleesi label says it is not indicated for HSDD in postmenopausal women or in men.[8]
The Vyleesi label's recommended dosage is 1.75 mg subcutaneously in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity.[8]
The label says patients should not administer more than a single dose within 24 hours.[8]
The label notes that few patients in the phase 3 program received more than 8 doses per month.[8]
The label says administering doses close together may increase the risk of additive effects on blood pressure.[8]
The label gives a mean terminal half-life for bremelanotide of approximately 2.7 hours.[8]
WADA's list names kisspeptin and its agonist analogues.[2]
Common questions
Is kisspeptin the same as PT-141?
No. A review abstract describes bremelanotide (PT-141) as a melanocortin receptor agonist approved by FDA for acquired generalized HSDD in premenopausal women.[9]
Which is better for libido, kisspeptin or PT-141?
In two phase 3 studies bremelanotide significantly improved sexual desire and related distress versus placebo in premenopausal women with HSDD. The kisspeptin trial in women measured brain processing.[10]
Is kisspeptin FDA approved like PT-141?
The Drugs@FDA lookup for kisspeptin came back with 'No matches found!'.[15]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3[Not Available].Biomedical chromatography : BMC · 2024PMID 38978171Accessed 2 Oct 2026
- 4Analysis and Characterization of Kisspeptin and Its Analogues in Serum and Urine Samples by Liquid Chromatography-High-Resolution Mass Spectrometry for Doping Control Purposes.Drug testing and analysis · 2026PMID 42057309Accessed 2 Oct 2026
- 5Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026
- 6Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
- 7Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.JAMA network open · 2022PMID 36287566Accessed 2 Oct 2026
- 8These highlights do not include all the information needed to use VYLEESI ® safely and effectively. See full prescribing information for VYLEESI VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019FDA label (Vyleesi), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 9Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
- 10Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
- 11Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.The journal of sexual medicine · 2019PMID 31277966Accessed 2 Oct 2026
- 12PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND (bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab] OR Vyleesi[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.The Journal of clinical endocrinology and metabolism · 2011PMID 21632807Accessed 2 Oct 2026
- 14Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.The Journal of clinical endocrinology and metabolism · 2009PMID 19820030Accessed 2 Oct 2026
- 15Drugs@FDA (openFDA) search: active ingredient "kisspeptin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.